dalteparin has been researched along with Prostatic Neoplasms in 10 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using two examples, prostate cancer, and comparisons of single medications, we illustrated how the proposed changes in clinical research, matching strategy to each application, might be addressed." | 2.48 | Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research. ( Greenfield, S; Kaplan, SH, 2012) |
| " Logistic regression models were used to test the effect of LMWH dosage on all three outcomes." | 1.38 | Influence of low-molecular-weight heparin dosage on red blood cell transfusion, lymphocele rate and drainage duration after open radical prostatectomy. ( Budäus, L; Graefen, M; Heinzer, H; Huland, H; Jonas, L; Karakiewicz, PI; Larbig, R; Schlomm, T; Schmitges, J; Steuber, T; Trinh, QD, 2012) |
| "The risk of prostate cancer-specific mortality (PCSM) was compared between the AC and non-AC groups." | 1.38 | Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. ( Carroll, PR; Chan, JM; Choe, KS; Cowan, JE; D'Amico, AV; Liauw, SL, 2012) |
| "We discuss the cases of 2 patients with prostate cancer who were taking Dr." | 1.35 | Prostasol and venous thromboembolism. ( Bubley, G; Clement, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilts, IT | 1 |
| Hutten, BA | 1 |
| Meijers, JCM | 1 |
| Spek, CA | 1 |
| Büller, HR | 2 |
| Kamphuisen, PW | 1 |
| van Doormaal, FF | 1 |
| Di Nisio, M | 1 |
| Otten, HM | 1 |
| Richel, DJ | 1 |
| Prins, M | 1 |
| Greenfield, S | 1 |
| Kaplan, SH | 1 |
| Clement, J | 1 |
| Bubley, G | 1 |
| Schmitges, J | 1 |
| Trinh, QD | 1 |
| Jonas, L | 1 |
| Budäus, L | 1 |
| Larbig, R | 1 |
| Schlomm, T | 1 |
| Karakiewicz, PI | 1 |
| Heinzer, H | 1 |
| Huland, H | 1 |
| Graefen, M | 1 |
| Steuber, T | 1 |
| Choe, KS | 1 |
| Cowan, JE | 1 |
| Chan, JM | 1 |
| Carroll, PR | 1 |
| D'Amico, AV | 1 |
| Liauw, SL | 1 |
| González-Martín, A | 1 |
| Fernández, E | 1 |
| Vaz, MA | 1 |
| Burgos, J | 1 |
| López García, M | 1 |
| Rodríguez Patrón, R | 1 |
| Guillén, C | 1 |
| Mayayo, T | 1 |
| Allona, A | 1 |
| Arias, F | 1 |
| Moyano, A | 1 |
| Aho, T | 1 |
| Al-Hayek, S | 1 |
| Winterbottom, A | 1 |
| Koo, B | 1 |
| Warren, A | 1 |
| Tomita, N | 1 |
| Kanamori, H | 1 |
| Fujita, H | 1 |
| Maruta, A | 1 |
| Naitoh, A | 1 |
| Nakamura, S | 1 |
| Ota, Y | 1 |
| Nozue, N | 1 |
| Kihara, M | 1 |
| Ishigatsubo, Y | 1 |
| Strobbe, G | 1 |
| Pannier, D | 1 |
| Villain, A | 1 |
| Feutry, F | 1 |
| Marliot, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate[NCT00312013] | Phase 3 | 503 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Pediatric Robotic Versus Open Pyeloplasty: A Pilot Randomized Control Study[NCT04884945] | 14 participants (Actual) | Interventional | 2017-10-24 | Suspended (stopped due to Have not resumed recruitment post COVID. The study moved to data analysis only 2.22.23. After analyzing the data, study team may request permission to return to open enrollment.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Prostatic Neoplasms
| Article | Year |
|---|---|
Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research.
Topics: Anticoagulants; Comparative Effectiveness Research; Enoxaparin; Evidence-Based Medicine; Humans; Mal | 2012 |
3 trials available for dalteparin and Prostatic Neoplasms
| Article | Year |
|---|---|
Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Topics: Aged; Anticoagulants; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female | 2017 |
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2011 |
Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Admini | 2007 |
6 other studies available for dalteparin and Prostatic Neoplasms
| Article | Year |
|---|---|
Prostasol and venous thromboembolism.
Topics: Aged; Aged, 80 and over; Complementary Therapies; Dietary Supplements; Drugs, Chinese Herbal; Enoxap | 2008 |
Influence of low-molecular-weight heparin dosage on red blood cell transfusion, lymphocele rate and drainage duration after open radical prostatectomy.
Topics: Aged; Anticoagulants; Blood Loss, Surgical; Drainage; Enoxaparin; Erythrocyte Transfusion; Humans; L | 2012 |
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chemoprevention; Clopidogre | 2012 |
'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
Topics: Aged; Anticoagulants; Dalteparin; Diagnostic Errors; Embolization, Therapeutic; Erythrocyte Transfus | 2021 |
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
Topics: Aged; Benzamidines; Dalteparin; Drug Administration Schedule; Gabexate; Guanidines; Humans; Idarubic | 2001 |
First-time prescription of enzalutamide in a patient treated with fluindione and digoxin: serial drug interactions.
Topics: Aged; Atrial Fibrillation; Benzamides; Digoxin; Drug Interactions; Drug Overdose; Drug Substitution; | 2019 |